Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2017 2
2018 2
2019 1
2021 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.
Kanaya N, Kitamura Y, Lopez Vazquez M, Franco A, Chen KS, van Schaik TA, Farzani TA, Borges P, Ichinose T, Seddiq W, Kuroda S, Boland G, Jahan N, Fisher D, Wakimoto H, Shah K. Kanaya N, et al. Among authors: ichinose t. Sci Transl Med. 2023 May 31;15(698):eade8732. doi: 10.1126/scitranslmed.ade8732. Epub 2023 May 31. Sci Transl Med. 2023. PMID: 37256936 Free PMC article.
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M, Hasegawa H, Sumigama S, Aleksic B, Kodera Y, Kasuya H. Eissa IR, et al. Among authors: ichinose t. Cancers (Basel). 2018 Sep 26;10(10):356. doi: 10.3390/cancers10100356. Cancers (Basel). 2018. PMID: 30261620 Free PMC article. Review.
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.
Eissa IR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, Mukoyama N, Morimoto T, Miyajima N, Hitoki H, Sumigama S, Aleksic B, Kodera Y, Kasuya H. Eissa IR, et al. Among authors: ichinose t. Front Oncol. 2017 Jul 14;7:149. doi: 10.3389/fonc.2017.00149. eCollection 2017. Front Oncol. 2017. PMID: 28770166 Free PMC article. Review.
STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy.
Sibal PA, Matsumura S, Ichinose T, Bustos-Villalobos I, Morimoto D, Eissa IR, Abdelmoneim M, Aboalela MAM, Mukoyama N, Tanaka M, Naoe Y, Kasuya H. Sibal PA, et al. Among authors: ichinose t. Mol Oncol. 2024 Feb 23. doi: 10.1002/1878-0261.13603. Online ahead of print. Mol Oncol. 2024. PMID: 38400597 Free article.
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Miyajima N, Ragab Eissa I, Abdelmoneim M, Naoe Y, Ichinose T, Matsumura S, Bustos-Villalobos I, Mukoyama N, Morimoto D, Shibata M, Takeuchi D, Tsunoda N, Kikumori T, Tanaka M, Kodera Y, Kasuya H. Miyajima N, et al. Among authors: ichinose t. Nagoya J Med Sci. 2021 Nov;83(4):683-696. doi: 10.18999/nagjms.83.4.683. Nagoya J Med Sci. 2021. PMID: 34916713 Free PMC article.
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment.
Eissa IR, Mukoyama N, Abdelmoneim M, Naoe Y, Matsumura S, Bustos-Villalobos I, Ichinose T, Miyajima N, Morimoto D, Tanaka M, Fujimoto Y, Sone M, Kodera Y, Kasuya H. Eissa IR, et al. Among authors: ichinose t. Int J Cancer. 2021 Jul 1;149(1):214-227. doi: 10.1002/ijc.33550. Epub 2021 Mar 23. Int J Cancer. 2021. PMID: 33687756 Free article.
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth.
Wu Z, Ichinose T, Naoe Y, Matsumura S, Villalobos IB, Eissa IR, Yamada S, Miyajima N, Morimoto D, Mukoyama N, Nishikawa Y, Koide Y, Kodera Y, Tanaka M, Kasuya H. Wu Z, et al. Among authors: ichinose t. Mol Ther Oncolytics. 2019 May 13;13:107-115. doi: 10.1016/j.omto.2019.04.004. eCollection 2019 Jun 28. Mol Ther Oncolytics. 2019. PMID: 31193737 Free PMC article.
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, Hotta Y, Shikano T, Yamada S, Kanzaki A, Fujii T, Sugimoto H, Nomoto S, Nishikawa Y, Tanaka M, Tsurumaru N, Kuwahara T, Fukuda S, Ichinose T, Kikumori T, Takeda S, Nakao A, Kodera Y. Tan G, et al. Among authors: ichinose t. Int J Cancer. 2015 Apr 1;136(7):1718-30. doi: 10.1002/ijc.29163. Epub 2014 Sep 27. Int J Cancer. 2015. PMID: 25156870 Free article.
11 results